We provide the latest news
from the world of economics and financeBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.
At Allogene Therapeutics, a filing with the SEC revealed that on Thursday, Director Arie Belldegrun purchased 1,724,137 shares of ALLO, at a cost of $2.90 each, for a total investment of $5M. Allogene Therapeutics is trading up about 7.3% on the day Tuesday.
And at Nikola, there was insider buying on Monday, by Chief Executive Officer Stephen J. Girsky who purchased 1,000,000 shares for a cost of $0.54 each, for a trade totaling $540,000. Nikola is trading up about 7.4% on the day Tuesday. Girsky was up about 5.9% on the purchase at the high point of today's trading session, with NKLA trading as high as $0.57 at last check today.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.